KEYNOTE-059 (Cohort 1): Pembrolizumab Monotherapy in Previously Treated Advanced Gastric or GEJ Adenocarcinoma

June 2-6, 2017; Chicago, Illinois
Pembrolizumab well tolerated, produced durable responses in patients with pretreated, advanced gastric/GEJ cancer, with highest responses in PD-L1–positive subgroup.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.36 MB
Released: June 13, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings